Literature DB >> 14610009

Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

Ling Tao1, Hui-Rong Liu, Erhe Gao, Zhi-Ping Teng, Bernard L Lopez, Theodore A Christopher, Xin-Liang Ma, Ines Batinic-Haberle, Robert N Willette, Eliot H Ohlstein, Tian-Li Yue.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor (PPAR) signaling pathways have been reported to exert anti-inflammatory effects and attenuate atherosclerosis formation. However, the mechanisms responsible for their anti-inflammatory and antiatherosclerotic effects remain largely unknown. The present study tested the hypothesis that a PPARgamma agonist may exert significant endothelial protection by antioxidative and antinitrative effects. METHODS AND
RESULTS: Male New Zealand White rabbits were randomized to receive a normal (control) or a high-cholesterol diet and treated with vehicle or rosiglitazone (a PPARgamma agonist) 3 mg x kg(-1) x d(-1) for 5 weeks beginning 3 weeks after the high-cholesterol diet. At the end of 8 weeks of a high-cholesterol diet, the rabbits were killed, and the carotid arteries were isolated. Bioactive nitric oxide was determined functionally (endothelium-dependent vasodilatation) and biochemically (the phosphorylation of vasodilator-stimulated phosphoprotein, or P-VASP). Vascular superoxide production, PPARgamma, gp91phox, and inducible nitric oxide synthase (iNOS) expression, and vascular ONOO- formation were determined. Hypercholesterolemia caused severe endothelial dysfunction and reduced P-VASP, despite a marked increase in iNOS expression and total NOx production. Treatment with rosiglitazone enhanced PPARgamma expression, improved endothelium-dependent vasodilatation, preserved P-VASP, suppressed gp91phox and iNOS expression, reduced superoxide and total NOx production, and inhibited nitrotyrosine formation.
CONCLUSIONS: The PPARgamma agonist rosiglitazone exerted a significant vascular protective effect in hypercholesterolemic rabbits, most likely by attenuation of oxidative and nitrative stresses. The endothelial protective effects of PPARgamma agonists may reduce leukocyte accumulation in vascular walls and contribute to their antiatherosclerotic effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610009     DOI: 10.1161/01.CIR.0000097003.49585.5E

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

1.  The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.

Authors:  Ishwarlal Jialal; Harmeet Kaur
Journal:  Curr Diab Rep       Date:  2012-02-08       Impact factor: 4.810

2.  Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

Authors:  Yutaka Mori; Yohta Itoh; Tohru Obata; Naoko Tajima
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.

Authors:  Maria A Potenza; Sara Gagliardi; Leonarda De Benedictis; Addolorata Zigrino; Edy Tiravanti; Giuseppe Colantuono; Antonio Federici; Loredana Lorusso; Vincenzo Benagiano; Michael J Quon; Monica Montagnani
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

Review 4.  Senescence suppressors: their practical importance in replicative lifespan extension in stem cells.

Authors:  Eun Seong Hwang
Journal:  Cell Mol Life Sci       Date:  2014-07-23       Impact factor: 9.261

5.  Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

Authors:  Ningning Wang; J David Symons; Hui Zhang; Zhanjun Jia; Frank J Gonzalez; Tianxin Yang
Journal:  Toxicol Pathol       Date:  2008-12-15       Impact factor: 1.902

6.  Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.

Authors:  Xiao Lu; Xiaomei Guo; Sotirios K Karathanasis; Karen M Zimmerman; Jude E Onyia; Richard G Peterson; Ghassan S Kassab
Journal:  Cardiovasc Diabetol       Date:  2010-05-19       Impact factor: 9.951

7.  Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Authors:  Ling Tao; Yajing Wang; Erhe Gao; Hangxiang Zhang; Yuexing Yuan; Wayne B Lau; Lawrence Chan; Walter J Koch; Xin L Ma
Journal:  Circ Res       Date:  2009-11-25       Impact factor: 17.367

8.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

9.  Effects of rosiglitazone on native low-density-lipoprotein-induced respiratory burst in circulating monocytes and on the leukocyte-endothelial interaction in cholesterol-fed rats.

Authors:  Long Sheng Lu; Li Man Hung; Chang Hui Liao; Chau Chung Wu; Ming Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-21       Impact factor: 3.000

10.  Anti-oxidant and Anti-hypercholesterolemic Activities of Wasabia japonica.

Authors:  Young Sun Lee; Jae Ha Yang; Man Jong Bae; Wang Keun Yoo; Shen Ye; Charlie C L Xue; Chun Guang Li
Journal:  Evid Based Complement Alternat Med       Date:  2008-06-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.